Peroxisome proliferator-activated receptor gamma: a novel therapeutic target for cognitive impairment and mood disorders that functions via the regulation of adult neurogenesis

2021 ◽  
Author(s):  
Juhee Lim ◽  
Hyo In Kim ◽  
Yeojin Bang ◽  
Hyun Jin Choi
Keyword(s):  
Cognitive Impairment ◽  
Mood Disorders ◽  
Adult Neurogenesis ◽  
Therapeutic Target ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Novel Therapeutic

scholarly journals Peroxisome proliferator-activated receptor α as a novel therapeutic target for schizophrenia

EBioMedicine ◽  
2020 ◽  
Vol 62 ◽  
pp. 103130
Author(s):  
Yuina Wada ◽  
Motoko Maekawa ◽  
Tetsuo Ohnishi ◽  
Shabeesh Balan ◽  
Shigeru Matsuoka ◽  
...  
Keyword(s):  
Therapeutic Target ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Novel Therapeutic

scholarly journals Neuroprotective Potential of Peroxisome Proliferator Activated Receptor-αAgonist in Cognitive Impairment in Parkinson’s Disease: Behavioral, Biochemical, and PBPK Profile

PPAR Research ◽  
2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Dedeepya Uppalapati ◽  
Nihar R. Das ◽  
Rahul P. Gangwal ◽  
Mangesh V. Damre ◽  
Abhay T. Sangamwar ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Neurodegenerative Disorder ◽  
Memory Loss ◽  
Pbpk Modeling ◽  
Pharmacokinetic Parameters ◽  
Peroxisome Proliferator ◽  
Fenofibric Acid ◽  
Peroxisome Proliferator Activated Receptor

Parkinson’s disease (PD) is a common neurodegenerative disorder affecting 1% of the population by the age of 65 years and 4-5% of the population by the age of 85 years. PD affects functional capabilities of the patient by producing motor symptoms and nonmotor symptoms. Apart from this, it is also associated with a higher risk of cognitive impairment that may lead to memory loss, confusion, and decreased attention span. In this study, we have investigated the effect of fenofibrate, a PPAR-αagonist in cognitive impairment model in PD. Bilateral intranigral administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (100 µg/1 µL/side) produced significant cognitive dysfunctions. Fenofibrate treatment at 10, 30, and 100 mg/kg for twenty-five days was found to be neuroprotective and improved cognitive impairment in MPTP-induced PD model as evident from behavioral, biochemical (MDA, GSH, TNF-α, and IL-6), immunohistochemistry (TH), and DNA fragmentation (TUNEL positive cells) studies. Further, physiologically based pharmacokinetic (PBPK) modeling study was performed using GastroPlus to characterize the kinetics of fenofibric acid in the brain. A good agreement was found between pharmacokinetic parameters obtained from the actual and simulated plasma concentration-time profiles of fenofibric acid. Results of this study suggest that PPAR-αagonist (fenofibrate) is neuroprotective in PD-induced cognitive impairment.

Peroxisome proliferator activated receptor gamma (PPARγ) as a therapeutic target for improvement of cognitive performance in Fragile-X

2014 ◽  
Vol 82 (3) ◽  
pp. 291-294 ◽  
Author(s):  
Mohammad Jodeiri Farshbaf ◽  
Kamran Ghaedi ◽  
Mahsa Shirani ◽  
Mohammad Hossein Nasr-Esfahani
Keyword(s):  
Cognitive Performance ◽  
Therapeutic Target ◽  
Fragile X ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor
Sign in / Sign up

Export Citation Format

Share Document